Free and Total Platelet Glycoprotein IIb/IIIa Measurement in Whole Blood by Quantitative Flow Cytometry during and after Infusion of c7E3 Fab in Patients Undergoing PTCA

Summary

A quantitative flow cytometry assay was used to evaluate the ex vivo kinetics of c7E3 Fab platelet effect in 16 patients undergoing PTCA treated with abciximab and compared with aggregometry assay. Immunolabeling of platelets was directly assessed on whole blood, using in parallel two monoclonal antibodies (Mabs) raised against GPIIIa, Mab1, the binding of which is inhibited by c7E3 Fab, and Mab2, the binding of which is not affected by c7E3 Fab. We found a severe and sustained inhibition of both GPIIb/IIIa receptors and platelet functions. The inter-individual variation in response to abciximab was low. A significant transient increase at H24 and H48 in the binding of Mab2 was found as an unexpected result, and confirmed in vitro. Results demonstrate that flow cytometry is a reliable method in agreement with aggregation. In addition, our results show that it is a standardized tool and a time-saving technique.

• References

• 1 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64.
• 2 The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:: 956-61.
• 3 The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:: 1689-96.
• 4 The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:: 1429-35.
• 5 The EPISTENT Investigators Randomised controlled trial to assess safety of coronary stenting with use of abciximab. Lancet 1998; 352:: 85-90.
• 6 Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijissen KM, Stibbe J, de Feyter PJ. and the European Cooperative Study Group. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89:: 596-603.
• 7 Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
• 8 Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 1997; 96: 1130-8.
• 9 Kereiakes DJ, Kleiman N, Fergusson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemolifiban in 170 patients after coronary Stent deployment. Circulation 1997; 96: 1117-21.
• 10 Coller VS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-7.
• 11 Wagner C, Mace K, Mascelli MA, DeRita R, Lance E, Weisman H, Ghrayeb J, Jordan R. Pharmacodynamics of ReoPro (c7E3 Fab): free plasma levels determine clinical efficacy. Thromb Haemost 1997; S7-8. Abstract
• 12 Riederer MA, Steiner B. The extend of platelet aggregation is dependent on the free GPIIb/IIIa concentration and not the % receptor occupancy. Thromb Haemost 1997; S6-7. Abstract
• 13 Gawaz M, Neumann FJ, Ott I, Schiessler A, Schöming A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
• 14 Gawaz M, Neumann FJ, Ott I, May A, Schöming A. Platelet activation and coronary Stent implantation. Effect of thrombotic therapy. Circulation 1996; 94: 279-85.
• 15 Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Volksw D, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
• 16 Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-36.
• 17 Besson I, Hézard N, Metz D, Daliphard S, Maes D, Simon G, Potron G. Monitoring of new therapeutical anti-GPIIb/IIIa using a quantitative flow cytometry method. Thromb Haemost 1997; S8. Abstract
• 18 Potron G, Daliphard S, d’Hautcourt JL, Dutrillaux F, Racadot E, Hézard N, Besson I. Quantitative measurement of platelet membrane glycoprotein (GpIIIa) by flow cytometry. Anal Cell Pathol 1997; 13: 143 Abstract
• 19 Dechavane M, Ffrench M, Pages J, Boukerche H, Bryon PA, McGregor JL. Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemost 1987; 57: 106-9.
• 20 Lu X, Williams JA, Deadman JJ, Salmon GP, Kakkar VV, Wilkinson JM, Baruch D, Authi KS, Rhaman S. Preferential antagonism of the interactions of the integrin αIIbβ3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Biochem J 1994; 304: 929-56.
• 21 Mascelli MA, Worley S, Verabio NJ, Lance HT, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 1997; 96: 3860-6.
• 22 Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-36.
• 23 Metcalfe P, Williamson LM, Reutelingsperger CPM, Swann I. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997; 98: 86-95.
• 24 Anderson DR, Zayed E, Embree J, Theroux P, Steiner B. Flow cytometry as a quantitative measure of the antiplatelet activity of a glycoprotein IIb/IIIa inhibitor. Blood 1997; 86: 893 Abstract
• 25 Liu CZ, Hur BT, Huang TF. Measurement of glycoprotein IIb/IIIa blockade by cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins. Thromb Haemost 1996; 76: 585-91.
• 26 Jordan RE, Mascelli MA, Nakada MT, Weisman HF. Abciximab causes profound, immediate inhibition of platelet function that recovers gradually after PTCA. Circulation 1997; 96: I-721. Abstract
• 27 Perlemuter K, Masse JM, Debili N, Cramer E. Intracellular trafficking of monoclonal antibody fragment against glycoprotein IIb/IIIa, c7E3 Fab, in human cultured megakaryocytes. Circulation 1997; 96: I-3. Abstract
• 28 Perlemuter K, Ajzenberg N, Masse JM, Dubois-Rande JL, Dupouy P, Baruch D, Castaigne A, Cramer E. Monoclonal antibody fragment against glycoprotein IIb/IIIa, c7E3 Fab, prevents shear stress-induced platelet shape change in vitro and in vivo. Circulation 1997; 96: I-3. Abstract
• 29 Nurden P. Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 1997; 78: 1305-15.
• 30 Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8.
• 31 Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβIII) inhibitors. Blood 1998; 92: 3240-9.
• 32 Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, Matsuzawa Y. Association between ligand-induced conformational changes of integrin αIIbβ3 and αIIbβ3-mediated intracellular Ca2+ signaling. Blood 1998; 92: 3675-83.
• 33 Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.